Literature DB >> 32633617

Qualitative accounts of PrEP discontinuation from the general population in Eswatini.

Kate Bärnighausen1, Pascal Geldsetzer2,3, Sindy Matse4, Anita Hettema5, Allison B Hughey5, Phiwa Dlamini5, Mxolisi Mavuso5, David Fakudze5, Kathleen Kahn1, Till Bärnighausen2, Shannon A McMahon2,6.   

Abstract

People in receipt of pre-exposure prophylaxis (PrEP) for the prevention of HIV in Sub-Saharan Africa often discontinue taking the medication. We conducted 27 semi-structured interviews with men and women who had started PrEP but did not return to the clinic for a refill after a 1, 2 or 3-month period. These 'discontinuation' clients were enrolled in a PrEP demonstration project for the general population in nurse-led, public-sector, primary-care clinics in Eswatini. Reasons for discontinuation included changes to self-perceived HIV risk such as the end of pregnancy and absent partners. Others described PrEP as inaccessible when working away from home and many described difficulties relating to a daily pill regimen and managing side effects. Female clients described being prohibited from using PrEP by their partners and co-wives. From these results, we recommend that client-centred counselling stresses the prevention-effective adherence paradigm, which promotes PrEP use in risk periods that are identifiable and PrEP discontinuation when the risk period has finished. A national scale up of PrEP may mitigate problems accessing PrEP. Extended counselling and support could assist with adherence and the management of side effects. Education and support for partners and families of PrEP clients may also contribute to better PrEP continuation.

Entities:  

Keywords:  Eswatini; HIV; PrEP; discontinuation; prevention-effective adherence

Year:  2020        PMID: 32633617     DOI: 10.1080/13691058.2020.1770333

Source DB:  PubMed          Journal:  Cult Health Sex        ISSN: 1369-1058


  7 in total

1.  Alignment of PrEP adherence with periods of HIV risk among adolescent girls and young women in South Africa and Zimbabwe: a secondary analysis of the HPTN 082 randomised controlled trial.

Authors:  Jennifer Velloza; Deborah Donnell; Sybil Hosek; Peter L Anderson; Z Mike Chirenje; Nyaradzo Mgodi; Linda-Gail Bekker; Mark A Marzinke; Sinead Delany-Moretlwe; Connie Celum
Journal:  Lancet HIV       Date:  2022-09-07       Impact factor: 16.070

2.  Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial.

Authors:  Sinead Delany-Moretlwe; James P Hughes; Peter Bock; Samuel Gurrion Ouma; Portia Hunidzarira; Dishiki Kalonji; Noel Kayange; Joseph Makhema; Patricia Mandima; Carrie Mathew; Elizabeth Spooner; Juliet Mpendo; Pamela Mukwekwerere; Nyaradzo Mgodi; Patricia Nahirya Ntege; Gonasagrie Nair; Clemensia Nakabiito; Harriet Nuwagaba-Biribonwoha; Ravindre Panchia; Nishanta Singh; Bekezela Siziba; Jennifer Farrior; Scott Rose; Peter L Anderson; Susan H Eshleman; Mark A Marzinke; Craig W Hendrix; Stephanie Beigel-Orme; Sybil Hosek; Elizabeth Tolley; Nirupama Sista; Adeola Adeyeye; James F Rooney; Alex Rinehart; William R Spreen; Kimberly Smith; Brett Hanscom; Myron S Cohen; Mina C Hosseinipour
Journal:  Lancet       Date:  2022-04-01       Impact factor: 202.731

3.  "I Just Decided to Stop:" Understanding PrEP Discontinuation Among Individuals Initiating PrEP in HIV Care Centers in Kenya.

Authors:  Fernandos K Ongolly; Annabel Dolla; Kenneth Ngure; Elizabeth M Irungu; Josephine Odoyo; Elizabeth Wamoni; Kathryn Peebles; Kenneth Mugwanya; Nelly R Mugo; Elizabeth A Bukusi; Jennifer Morton; Jared M Baeten; Gabrielle O'Malley
Journal:  J Acquir Immune Defic Syndr       Date:  2021-05-01       Impact factor: 3.771

4.  PrEP reminds me that I am the one to take responsibility of my life: a qualitative study exploring experiences of and attitudes towards pre-exposure prophylaxis use by women in Eswatini.

Authors:  Pia Juul Bjertrup; Nqobile Mmema; Velibanti Dlamini; Iza Ciglenecki; Qhubekani Mpala; Sindy Matse; Bernhard Kerschberger; Alison Wringe
Journal:  BMC Public Health       Date:  2021-04-14       Impact factor: 3.295

5.  Daily Oral Pre-exposure Prophylaxis (PrEP) Continuation Among Women from Durban, South Africa, Who Initiated PrEP as Standard of Care for HIV Prevention in a Clinical Trial.

Authors:  Ivana Beesham; Dvora L Joseph Davey; Mags Beksinska; Shannon Bosman; Jenni Smit; Leila E Mansoor
Journal:  AIDS Behav       Date:  2022-02-05

6.  Understanding PrEP decision making among pregnant women in Lilongwe, Malawi: A mixed-methods study.

Authors:  Lauren M Hill; Carol E Golin; Friday Saidi; Twambilile Phanga; Jennifer Tseka; Alinda Young; Lisa D Pearce; Suzanne Maman; Benjamin H Chi; Wilbroad Mutale
Journal:  J Int AIDS Soc       Date:  2022-09       Impact factor: 6.707

7.  Out-of-pocket Expenses and Time Spent on Clinic Visits Among HIV Pre-exposure Prophylaxis Users and Other Clinic Attendees in Eswatini.

Authors:  Stefan Kohler; Shona Dalal; Anita Hettema; Sindy Matse; Till Bärnighausen; Nicolas Paul
Journal:  AIDS Behav       Date:  2022-10-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.